Experience convenient blood cancer treatment close to home. Find out how this unique partnership brings autologous stem cell ...

Janssen Research & Development was granted FDA orphan designation for a treatment of multiple myeloma, according to a post to the agency’s ...

Tyler Sandahl, PharmD, of Mayo Clinic, and Michael Byrne, DO, of Tennessee Oncology, discuss practical advice for bringing ...

Many of you may remember from this column that I have multiple myeloma, or cancer of the bone marrow. In January, I will be headed to UVA hospital for a ...

Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with ...

Richard’s journey with multiple myeloma began in late 2020 with unrelenting back pain, fatigue, and breathing difficulties.

Researchers sought to determine whether cilta-cel would have similar results in a real-world RRMM population as in a clinical trial population.

GSK plc GSK announced that the FDA accepted its biologics license application (BLA) seeking approval for the Blenrep ...

Adaptive Biotechnologies posted strong Q3 results, beating expectations and reducing losses. Read why I maintain a Hold ...

Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies ...

The acquisition announcement came alongside the reveal of a Phase III failure for Roche’s TIGIT asset tiragolumab, which when ...